布洛芬凝胶与吡罗昔康凝胶治疗老年创伤性疼痛的比较:一项随机双盲试验
该前瞻性随机双盲对照研究纳入老年急诊肌肉骨骼损伤患者,布洛芬凝胶组70例、吡罗昔康凝胶组69例,首剂在急诊科外用,余剂量由患者在家自行每日三次外用共72小时。布洛芬组各时间点VAS较基线均显著下降(p<.001),VAS平均下降百分比显著高于吡罗昔康组(p<.001),临床疗效亦显著更高(p<.001),两组治疗相关不良事件无显著差异(p>.05)。结论提示对老年患者布洛芬凝胶是更有效的安全选择。
要点
- 老年急性肌肉骨骼损伤患者随机接受外用布洛芬(n=70)或外用吡罗昔康(n=69),首剂急诊外用,余量在家每日三次共72小时。
- 布洛芬组各时间点VAS较基线均显著下降(p<.001),VAS平均下降百分比显著高于吡罗昔康组(p<.001)。
- 布洛芬凝胶组临床疗效显著高于吡罗昔康凝胶组(p<.001)。
- 两组治疗相关不良事件无显著差异(p>.05)。
- 结论认为布洛芬凝胶对老年患者是安全选择且临床效果优于吡罗昔康凝胶。
适用人群与场景
- 老年急性肌肉骨骼损伤患者,于急诊科就诊并接受外用凝胶治疗。
诊断标准与关键阈值
- 采用视觉模拟量表(VAS)评分评估疼痛,于基线(V0)、60分钟(V1)、120分钟(V2)、24小时(V3)和72小时(V4)测量。
处置流程与药物剂量
- 第一步:在急诊科给予首剂外用凝胶(布洛芬或吡罗昔康)。
- 第二步:剩余剂量由患者在家自行外用,每日三次,持续72小时。
- 原文未提及具体药物浓度、单次剂量或单次涂抹量。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性、随机、对照、双盲研究;样本量:布洛芬组70例、吡罗昔康组69例;人群:老年急性肌肉骨骼损伤患者。
- 干预与对照:外用布洛芬凝胶 vs 外用吡罗昔康凝胶,首剂急诊外用,余量在家每日三次共72小时。
- 主要终点:布洛芬组各时间点VAS较基线均显著下降(p<.001):V0−V1为1.08(95%CI 0.56-1.61),V0−V2为1.09(95%CI 0.49-1.69),V0−V3为1.44(95%CI 0.81-2.07),V0−V4为1.59(95%CI 0.91-2.26)。
- 布洛芬组VAS平均下降百分比显著高于吡罗昔康组(p<.001);布洛芬凝胶组临床疗效显著更高(p<.001)。
- 不良事件:两组治疗相关不良事件无显著差异(p>.05)。
证据类型、等级与局限
- 证据类型:前瞻性随机双盲对照试验。
- 原文未述局限性。
对床旁实践的改变
- 对老年急性肌肉骨骼损伤患者,急诊可考虑外用布洛芬凝胶作为镇痛选择,原文显示其VAS下降百分比及临床疗效优于外用吡罗昔康凝胶,且不良事件无显著差异。
- 用药方案为急诊首剂外用后,患者在家每日三次外用共72小时。
- 原文未提及适用与不适用人群的进一步限定或常见陷阱。
指南或共识出处
- 原文未提及指南或共识出处;来源期刊为Am J Emerg Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to compare the analgesic efficacy of topical ibuprofen and topical piroxicam for acute musculoskeletal injuries.
METHODS: In this prospective, randomized, controlled, double-blinded study, geriatric patients were assigned to groups to receive either topical ibuprofen (n = 70) or topical piroxicam (n = 69). The first dose of gel was applied in the emergency department and the remaining doses were self-administered at home by the patients thrice daily for 72 h. For each patient, the initial baseline visual analog scale (VAS) score (V 0) was compared with the VAS scores at the 60 min (V1), 120 min (V2), 24 h (V3) and 72 h (V4) time points. The decreases in VAS scores, clinical effectiveness of the treatments, and incidence of adverse events were evaluated.
RESULTS: In the topical ibuprofen group, the VAS scores were significantly lower at each measurement time point compared to baseline (p < .001). The results were as follows: V0 -V: 1.08, 95% CI: 0.56-1.61; V0 -V2: 1.09, 95% CI: 0.49-1.69; V0 -V3: 1.44, 95% CI: 0.81-2.07; V0 -V4: 1.59, 95% CI: 0.91-2.26. The mean percentage decrease in the VAS scores in the topical ibuprofen group was significantly higher than that in the topical piroxicam group (p < .001). The clinical effect of treatment was found to be significantly higher for the ibuprofen gel group (p < .001). There was no substantial difference in treatment-related adverse events between the groups (p > .05).
CONCLUSION: Ibuprofen gel, which is a safe treatment option for geriatric patients, is more clinically effective than piroxicam gel. Response to Reviewers.
参考来源
- Dogruyol S, Kocak AO, Akbas I, et al. Comparison of ibuprofen and piroxicam gel in the treatment of trauma pain: A randomized double-blind trial of geriatric population. Am J Emerg Med. 2020. PMID: 33041145. doi:10.1016/j.ajem.2020.08.041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。